Pibrentasvir

Contraindicated

Pibrentasvir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Pibrentasvir Relugolix Orgovyx Explained Increased relugolix exposure Details Pibrentasvir Simvastatin Flolipid Explained Increased simvastatin exposure and increased risk of myopathy Details Pibrentasvir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Pibrentasvir Atogepant Qulipta Increased atogepant exposure Details Pibrentasvir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Pibrentasvir Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Pibrentasvir Cyclosporine Injection Atopica Increased pibrentasvir exposure and an increased cycloSPORINE exposure Details Pibrentasvir Cyclosporine Ophthalmic Cequa Increased pibrentasvir exposure and an increased cycloSPORINE exposure Details Pibrentasvir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Pibrentasvir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Pibrentasvir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Pibrentasvir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Pibrentasvir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Pibrentasvir Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Pibrentasvir Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Pibrentasvir Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Pibrentasvir Lovastatin Altocor® Increased lovastatin exposure and increased risk of myopathy Details Pibrentasvir Methylergonovine Methergine Increased methylergonovine exposure Details Pibrentasvir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Pibrentasvir Nifedipine Adalat® Increased NIFEdipine exposure Details

Moderate

Pibrentasvir Acarbose Prandase® Explained Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Alogliptin Nesina Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Canagliflozin Invokana Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Dapagliflozin Farxiga Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Digoxin Cardoxin® Increased digoxin exposure and increased risk of digoxin toxicity Details Pibrentasvir Dofetilide Tikosyn Increased dofetilide exposure Details Pibrentasvir Dulaglutide Injection Trulicity Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Empagliflozin Glyxambi® (as a combination product containing Empagliflozin and Linagliptin) Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Ertugliflozin Steglatro Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Exenatide Injection Bydureon Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Fluvastatin Lescol Increased fluvastatin exposure and increased risk of myopathy Details Pibrentasvir Glimepiride Amaryl Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Glipizide Glucotrol Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Pibrentasvir Hydrocortisone Injection A-Hydrocort® Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Pibrentasvir Insulin Degludec (Rdna Origin) Injection Ryzodeg® (as a combination product containing Insulin Degludec and Insulin Aspart) Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Insulin Detemir (Rdna Origin) Injection Levemir Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Insulin Glulisine (Rdna Origin) Injection Apidra Altered glycemic control resulting in severe symptomatic hypoglycemia Details Pibrentasvir Linagliptin Tradjenta Altered glycemic control resulting in severe symptomatic hypoglycemia Details